Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
Status:
Completed
Trial end date:
2020-05-15
Target enrollment:
Participant gender:
Summary
An investigator initiated pilot trial: two arm, double blind, placebo controlled, randomized,
parallel group of approximately 750 patients with chronic kidney disease, and who have
evidence of overt proteinuria, will be treated with micro-particle curcumin versus placebo
over 24 weeks from start of the investigational medication date (approximately 6 months) to
test whether curcumin can slow chronic kidney disease progression in patients. Three 30 mg
capsules of micro-particle curcumin will be self-administered once daily in the morning to
determine the the safety and efficacy of curcumin relative to placebo in reducing albuminuria
and slowing the loss of eGFR.
Phase:
Phase 3
Details
Lead Sponsor:
Lawson Health Research Institute
Collaborators:
Canadian Institutes of Health Research (CIHR) The Kidney Foundation of Canada